Highest-materiality recent filing
Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.
IGC Pharma issues 4.27M shares to CEO and PFO to cancel $1.15M in debt
CEO Ram Mukunda receives 2,226,475 shares for cancellation of $601,148 owed, including $283,639 in cash advances.
IGC Pharma extends $12M loan agreement with O-Bank; facility fee rises to $60,000
Entered amendment to extend Master Loan and Security Agreement with O-Bank Co., Ltd.
IGC Pharma raises $514K via two convertible promissory notes with OID
FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.
IGC Pharma partners with New to The Street for 12-part national media campaign
12-part campaign includes TV interviews on Fox Business and Bloomberg Television.
IGC Pharma issues $353K convertible note to Vanquish Funding; also obtains $219K loan
Principal $353,050 includes $46,050 original issue discount; net proceeds $307,000 for working capital.
IGC Pharma raises ~$234k in registered direct offering of 780k shares at $0.30/share
Issued 779,997 shares of common stock at $0.30 per share for gross proceeds of ~$234k.
IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025
Board approved fiscal year change from March 31 to December 31, effective Dec 31, 2025.
IGC Pharma increases authorized common stock from 150M to 600M shares
Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.
IGC Pharma closes sale of Vancouver facility assets for ~$2.7M in non-cash consideration
Closed Nov 13, 2025; subsidiary Holi Hemp sold equipment, inventory, and leasehold assets to Wellness Essentials Northwest LLC.
IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant
Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.
IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M
Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.
IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients
Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.
IGC Pharma sells 588,235 shares to director-owned entity for $200,000 at $0.34 each
Shares issued to Moran Global Strategies, owned by director James Moran, at $0.34/share.
IGC Pharma stockholders re-elect two directors, ratify auditor, approve 5M share grant
Richard Prins (26,116,740 for) and Terry Lierman (27,800,503 for) re-elected as Class B directors until 2027.
IGC Pharma extends loan agreement with O-Bank; facility fees cut to $84,000 from $120,000
Extension effective July 8, 2024, extends term of existing Master Loan and Security Agreement under same terms.
IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation
Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
IGC Pharma announces $3M private placement with Bradbury Asset Management at $0.34/share
Issued 8,823,529 unregistered common shares at $0.34/share to Bradbury Asset Management on March 22, 2024.
IGC Pharma enters ATM sales agreement for up to $60M in common stock
Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of up to $60 million in common stock.
IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline
Terry Lierman appointed as independent Class B director, effective March 12, 2024.
IGC Pharma enters $60M ATM equity offering with A.G.P./Alliance Global Partners
On Oct 27, 2023, IGC Pharma entered an ATM sales agreement with A.G.P./Alliance Global Partners to sell up to $60M of common stock.
IGC Pharma shareholders pass all five proposals at 2023 annual meeting
Claudia Grimaldi elected Class A director with 14.7M for, 1.4M withheld, 11M broker non-votes.
IGC Pharma raises $3M in private placement of 10M shares at $0.30/sh
Gross proceeds of $3M from Bradbury Asset Management (≈$2B AUM) and three other investors.
IGC Pharma secures $12M revolving credit from O-Bank for Alzheimer's research
Up to $12M revolving credit facility; initial 12-month term with possible extension.
IGC Pharma enters 5-year employment agreement with PFO Claudia Grimaldi; $200k base salary
Five-year initial term with auto-renew; $200,000 annual base salary, subject to annual Board review.
India Globalization Capital rebrands as IGC Pharma, effective March 30, 2023
Name change to IGC Pharma, Inc. effective March 30, 2023; ticker symbol IGC unchanged.
Director John E. Lynch passes away; Jim Moran appointed to Audit and Compensation Committees
John E. Lynch, director since Jan 11, 2021, passed away on Dec 24, 2022.
IGC posts updated life sciences presentation on website; no financial or clinical updates
Presentation covers low-dose THC drug formulation and disease treatment initiatives.
IGC shareholders elect directors, ratify auditor, approve 3M share grant
Ram Mukunda, James Moran elected Class C directors until 2025; Claudia Grimaldi elected Class A director until 2023.
IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment
Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.
IGC subsidiary licenses NMI compounds from JNCASR for Alzheimer's treatment
Hamsa Biopharma (IGC subsidiary) obtains exclusive worldwide license for NMI Compounds from JNCASR.
IGC obtains final court approval of shareholder class action settlement; lawsuits dismissed
Court granted final approval of settlement on April 13, 2022, dismissing Tchatchou and Harris-Carr consolidated class actions.
IGC appoints Claudia Grimaldi to Board as non-independent director
Claudia Grimaldi appointed to the Board as non-independent director, effective March 23, 2022.
India Globalization Capital appoints former Congressman Jim Moran to board of directors
Appointed former Congressman Jim Moran as independent Class C director effective Jan 18, 2022.
Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.
IGC enters 5-year CEO employment agreement with Ram Mukunda; salary $360K
Employment agreement effective November 18, 2021; initial 5-year term with automatic 12-month renewals.
IGC shareholders approve director election, ratify auditor, and authorize 3.5M share equity grant
Richard Prins elected as Class B director, term through 2024 annual meeting.
On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.
On December 24, 2022, John E. Lynch, a Director of India Globalization Capital Inc. (the “Company” or “IGC”), passed away.
On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders
and Ms. Claudia Grimaldi was elected to the Company’s Board of Directors at the Annual Meeting, to serve as a Class A director, until the 2023 annual meeting of stockholders
On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders
On March 23, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” “IGC” or “we”) appointed Ms. Claudia Grimaldi (“Ms. Grimaldi”) to serve on the Board as a non-independent director.
On January 18, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” or “IGC”) appointed former Congressman Jim Moran (“Congressman Moran”) to serve on the Board as a Class C director.
On October 15, 2021, Richard Prins was elected to India Globalization Capital’s (the “Company”) Board of Directors at the Annual Meeting, to serve as a Class B director
Max materiality 0.85 · Median 0.55 · Most common event other_material